A global leader in applied proteomics, PS Biomarker Services provides specialist solutions for the discovery of novel biomarkers for the onset, progression and/or management of disease and new molecular targets for drug discovery through the application of its biomarker toolkit.

Following the initial human genome sequence in 2001 and the final report from the International Human Genome Sequencing Consortium in October 2004, researchers confirmed the existence of only 19,599 protein-coding genes, a number considerably below the 100,000 to 150,000 genes previously predicted. In turn, this has been further exacerbated by the major clinical problems in drugs experienced in September 2004 by Vioxx, Exanta, Prexige, Avastin, Galida and Lyrica resulting in an expected loss of over $15bn in annual sales. A whole new level of interest and attention has focused on the importance and value of biomarkers in drug development and protein expression in disease and enforces the crucial role that proteomics will play in unlocking value from exploiting functional genomics.

Proteome Sciences has strategic alliances with pharmaceutical and biotechnology companies to apply PS Biomarker Services for the discovery of biomarkers and disease targets in addition to pursuing an active biomarker discovery programme and the development of rapid MS assays.

Focusing primarily on the proteomics of human tissues and body fluids, Proteome Sciences has amassed a large collection of patent protected biomarkers in key human therapeutic areas including neurological, cardiovascular and metabolic diseases and oncology. These are out-licensed for diagnostic, prognostic and therapeutic applications. Revenue is generated from a combination of upfront, milestone and royalty payments, strategic alliances, funded research, grant income and royalties from biomarkers and reagents.

PS Biomarker Services

Focus:

Areas of novel application: